Research programme: viral encephalitis therapeutics - VGX PharmaceuticalsAlternative Names: VGX 2000
Latest Information Update: 31 Aug 2009
At a glance
- Originator VGX Pharmaceuticals
- Developer Inovio Biomedical Corporation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Encephalitis virus infections
Most Recent Events
- 29 Mar 2007 Preclinical trials in Encephalitis virus infections in USA (unspecified route)